ArticleEmerging infectious diseases
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.
Article in Emerging infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 200 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 1 synthesis or guideline pooled it, 698 citations in OpenAlex.
- Quantifying antimicrobial resistance in food-producing animals in North America.Frontiers in microbiology · 2025Pooled it
- Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution.Nature medicine · 2019Trial
- Comparative Performance and Species-Specific Recovery Biases of Culture-Based Methods forVeterinary sciences · 2026Review
- Recurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts.Gut pathogens · 2026Article
- A One Health Perspective onMicroorganisms · 2026Review
- Phenotypic Resistance of Ciprofloxacin and Azithromycin ResistantbioRxiv : the preprint server for biology · 2026Article
- A Comprehensive Review on Discovery, Development, the Chemistry of Quinolones, and Their Antimicrobial Resistance.Current topics in medicinal chemistry · 2026Review
- Antimicrobial use onFrontiers in microbiology · 2026Article
- Strain sharing and mobile genetic elements shape the interconnected resistomes of Campylobacter coli in Brazil.BMC biology · 2025Article
- Identification and Functional Characterization of the Polymerizing Glycosyltransferase Required for the Transfer of d-Ribose to the d-GalBiochemistry · 2025Article
- Comparative Genomic Analysis of Livestock-DerivedJournal of microbiology and biotechnology · 2025Article
- Natural Solutions to Antimicrobial Resistance: The Role of Essential Oils in Poultry Meat Preservation with Focus on Gram-Negative Bacteria.Foods (Basel, Switzerland) · 2024Review
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Genetic Diversity, Virulence, and Antibiotic Resistance Determinants ofPathogens (Basel, Switzerland) · 2024Article
- Persistence ofPathogens (Basel, Switzerland) · 2024Article
- Fluoroquinolone-resistantJAC-antimicrobial resistance · 2024Article
- Impact of Veterinary Feed Directive Rules Changes on the Prevalence of Antibiotic Resistance Bacteria Isolated from Cecal Samples of Food-Producing Animals at US Slaughterhouses.Pathogens (Basel, Switzerland) · 2024Article
- Acquisition and clearance dynamics of Campylobacter spp. in children in low- and middle-income countries.Epidemics · 2024Article
- Design of dot-blot hybridization assay for simultaneous detection ofAnnals of medicine and surgery (2012) · 2024Article
- Joining Forces against Antibiotic Resistance: The One Health Solution.Pathogens (Basel, Switzerland) · 2023Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinolone-resistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.